In conclusion, our investigation has identified that miR-125a-5p in serum may be a convenient and reliable biomarker for prognosis in breast cancer and that miR-125a-5p plays an important role to suppress tumorigenesis by directly targeting HDAC4. This evidence concerns the gene HDAC4 and breast carcinoma.